Animesh Pardanani

62PUBLICATIONS
87CO-AUTHORS
Haematological tumoursGene and molecular therapyCardiology (incl. cardiovascular diseases)Economic models and forecastingPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (62)

|Sep 18, 2026
Venetoclax Plus Hypomethylating Agent for 7- Versus 14- Versus 21- Versus 28-Day Cycles in Newly-Diagnosed Acute Myeloid Leukemia: ELN and Mayo Genetic Risk-Stratified Analysis in 540 Patients.

|Aug 23, 2026
Older Age, STAG2, and DNMT3A Mutations Predict Superior Posttransplant Survival in Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents.

|Jul 25, 2026
Risk-Adjusted Comparison of Survival in Chronic Myelomonocytic Leukemia With and Without Allogeneic Stem Cell Transplant: Mayo Clinic Experience in 775 Consecutive Patients.

|Jul 18, 2026
Acute Myeloid Leukemia Subtype-Specific Prognostic Value of NGS in the Setting of Intensive Chemotherapy.

|Sep 25, 2025
Validation of BLAST and BLAST-Mol Risk Models in Chronic Myelomonocytic Leukemia: Mayo-Humanitas Collaborative Project Involving 1101 Patients.

Saubia Fathima, Ali Alsugair, Muhammad Yousuf

|Sep 03, 2025
Triple A Plus (AAA +) Survival Prediction Model for Essential Thrombocythemia: Analysis Involving 7308 Patients.

Ayalew Tefferi, Giuseppe G Loscocco, Lior Rokach

Pageof 11

Frequent Collaborators

55 joint publications

Ayalew Tefferi

50 joint publications

Naseema Gangat

25 joint publications

Aref Al-Kali

24 joint publications

Kebede H Begna